• All Share : 48647.62
    UNCHANGED0.00%
    Top 40 : 4198.50
    UNCHANGED0.00%
    Financial 15 : 13696.23
    UNCHANGED0.00%
    Industrial 25 : 55226.68
    UNCHANGED0.00%

  • ZAR/USD : 10.5831
    UP 0.08%
    ZAR/GBP : 17.7647
    UP 0.11%
    ZAR/EUR : 14.6302
    UP 0.11%
    ZAR/JPY : 0.1035
    UP 0.26%
    ZAR/AUD : 9.8331
    UP 0.13%

  • Gold : 1287.1400
    UP 0.26%
    Platinum : 1405.0000
    UP 0.29%
    Silver : 19.4859
    UP 0.23%
    Palladium : 787.0000
    UP 0.64%
    Brent Crude Oil : 109.290
    UP 0.17%

  • All data is delayed by 15 min. Data supplied by I-Net Bridge
    Hover cursor over this ticker to pause.

Thu Apr 24 05:55:31 SAST 2014

R4.3 billion ARV tender for pharma companies

Sapa | 14 December, 2010 12:430 Comments

An antiretroviral (ARV) tender worth R4.3 billion over two years has been awarded to 10 pharmaceutical companies, says Health Minister Aaron Motsoaledi.

This represented a R4.7 billion saving over what the government had previously paid for rolling out ARVs.

"South Africa can now afford to treat twice as many people with the same amount of money," he told reporters in Pretoria on Tuesday.

"It is notable that these tender price reductions have been achieved through the same suppliers that are contracted in the current tender."

The new tender starts in January 2011 and runs for two years.

He attributed the lower tender price from the same suppliers to increased competition and a better tendering process.

Asked why the same suppliers were able to provide ARVs at a lower cost he replied: "Perhaps it was our mistake in government, perhaps we were sleeping."

He said he was not at this stage contemplating a "witchhunt" of suppliers who had overcharged. Some of the suppliers had claimed that at lower prices there would be substantial job losses, he said.

"I called their bluff. There are more profits in pharmaceuticals than in oil. My message to pharmaceuticals is that they are in a sector that is very sensitive. They mustn't fish from our troubled waters."

He said the government hoped to replicate the success of cutting the cost of procuring ARVs when it focused on the tender process for tuberculosis drugs, vaccines and drugs for the treatment of diseases related to maternal and child health.

To submit comments you must first

Join the discussion & Debate

R4.3 billion ARV tender for pharma companies

For Commenters Consideration | Please stick to the subject matter
Thu Apr 24 05:55:31 SAST 2014 ::

COMMENTS [0]